Jay Ariyawansa

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis

Clapton Dias, Kenneth Todd Moore, Joe Murphy et al. · American Journal of Nephrology · 2016 · 130 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban

Kenneth Todd Moore, Alexei N. Plotnikov, An Thyssen et al. · Journal of Cardiovascular Pharmacology · 2011 · 58 citations

Medicine, Pharmacology, Pharmacotherapy +17

Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers

Jerrold H. Levy, Kenneth Todd Moore, Matthew D. Neal et al. · Journal of Thrombosis and Haemostasis · 2017 · 50 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants

Damayanthi Devineni, Nicole Vaccaro, Joe Murphy et al. · International Journal of Clinical Pharmacology and Therapeutics · 2014 · 47 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

An open‐label study to estimate the effect of steady‐state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function

Kenneth Todd Moore, Seema Vaidyanathan, Jaya Natarajan et al. · The Journal of Clinical Pharmacology · 2014 · 45 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17